Search results

Sometimes it’s as simple as what limit is on the Zoom license (or whatever platform they’re using)

Great interview. Thanks to Chris and David. Really good to hear more about the project. Clearly a lot of work going on from a lot of people behind the scenes but the collaboration between AfME and Chris seems to continue to be really productive. We’re lucky to have people like this working on...

Oh no, hope it doesn’t knock you back too badly and you feel better soon :hug:

Audio only version for those who want it available here (audio ripped from youtube and converted into low bitrate mp3).

I’m not sure they do. I’m also not sure if it matters for the goals? This is in their FAQ

It is indeed a big survey. But we have plenty of time to complete it and can save our progress. There’s also a version to print and they seem to be offeribg some phone support for people who need it. They were also great at engaging earlier on in the design process. Lots of positives here, well...

And already a third of the way to the new target! Nice work :)

Sounds like it’s been selected for debate

It’s a shame the factsheet hasn’t been read and there’s some misunderstandings here. I completely get what you feel and felt a bit the same at first tbh. I wonder if there’s perhaps a difference or clash in style adding to things here? The length of the response and the point by point detail...

Some great comments by others which I support and @Nightsong highlights how important it is to get this right. And thanks to @TheDePaulGroup for the involvement and comprehensive responses so far. While we’re discussing differences there is a lot of shared understanding in here too I think...

I don’t think so and this was the question I had in the other thread about mechanisms of resistance to daratumumab in multiple myeloma There seems to be a lot of focus on NK cell quantity but less on other details which could be important here. I’d like to understand more or find out if studies...

I found this interesting in general and thought others would. A scientific development with potentially relevant applications and also ties in with recent discussion of usefulness of AI/ML. I also think it’s an area @Jonathan Edwards is very familiar with!

Microsoft AI Research has made a tool called Skala available for everyone to use. It was previously an internal research project. Here’s the new Azure Skala page. What is this all about? There’s some info this webpage about the DFT research project Most accessible is probably this blogpost...

Great work @Joan Crawford and thank you, am sharing where I can to try and get some eyes and donations to help your efforts

Agree that focussing on predefined activities is the wrong path. Different people of different severities with different levels of support prioritise different things. This just isn’t an accessible questionnaire, in size or structure. I gave up on it. I believe there will be self selection in...

Oh yeah… I’d missed that! Thanks both for the explanation. Thanks for the insight. Useful to know.

If you did want to Khan Academy has a couple of good modules This AP Biology one And this MCAT module

Or they’ve got a good PR team? I was surprised to hear about it first from the media rather than here tbh.

Yeah, I think some of as are roughly saying the same thing. Maybe with some differences in how we dress it up. Others seem to think it’s not worth pursuing at all. It seems clear from the factors raised by Chris Ponting and Kevin McConway that this shouldn’t be being reported as a test with the...

The section on diagnostic value has some interesting bits too. I don’t think they’re completely ignoring the limitations here and they do call this a proof-of-concept study And on use of their technology Here are links to the papers referenced in this section for people who want to read...